Data as of .
BBP vs IDNA: which is really different?
BBP and IDNA hold 21% of their weight in the same names, and IDNA returned more over the year.
ETFIQ Off-Index Score: IDNA scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
21% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, BBP and IDNA hold 21% of their money in the same securities at the same weight.
| Holding | BBP | IDNA |
|---|---|---|
| IMMUNITYBIO INC | 4.83% | 2.94% |
| MODERNA INC | 2.50% | 9.54% |
| IOVANCE BIOTHERAPEUTICS INC | 2.45% | 3.67% |
| BIONTECH SE | 1.75% | 3.20% |
| EXELIXIS INC | 1.74% | 3.25% |
| INCYTE CORP | 1.60% | 3.60% |
| REGENERON PHARMACEUTICALS | 1.53% | 3.63% |
| VERTEX PHARMACEUTICALS INC | 1.52% | 3.34% |
| CRISPR THERAPEUTICS AG | 1.48% | 1.50% |
| NOVAVAX INC | 1.93% | 1.46% |
| KURA ONCOLOGY INC | 1.39% | 0.93% |
| NUVATION BIO INC | 0.85% | 1.33% |
| Only in BBP | Only in IDNA |
|---|---|
| APELLIS PHARMACEUTICALS INC 2.60% | TWIST BIOSCIENCE 7.09% |
| KALVISTA PHARMACEUTICALS INC 2.53% | GENMAB 4.13% |
| MIRUM PHARMACEUTICALS INC 2.40% | BAYER AG 3.87% |
| AXSOME THERAPEUTICS INC 2.25% | REVOLUTION MEDICINES 3.76% |
| KINIKSA PHARMACEUTICALS INTERNATIONAL PL 2.07% | TAKEDA PHARMACEUTICAL 3.62% |
| ROIVANT SCIENCES LTD 2.07% | MERCK & CO INC 3.57% |
| ZAI LAB LTD 1.95% | CARIS LIFE SCIENCES 3.39% |
| BIOCRYST PHARMACEUTICALS INC 1.94% | ROCHE PS PAR AG 3.09% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Sep 18, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| BBP | IDNA | BBP | IDNA | BBP | IDNA | |
| 3 months | +15.3% | +30.3% | +13.1 pts | +28.1 pts | +17.8 pts | +32.8 pts |
| 6 months | +29.5% | +41.4% | +11.5 pts | +23.4 pts | +5.3 pts | +17.2 pts |
| 1 year | +47.5% | +73.4% | +30.9 pts | +56.9 pts | +25.7 pts | +51.7 pts |
| 3 years | +103.0% | +91.3% | +24.6 pts | +12.9 pts | +4.8 pts | −6.9 pts |
| Since launch | +304.4% | +69.7% | −56.6 pts | −123.9 pts | −371.1 pts | −242.0 pts |
| BBP Virtus Biotech ETF Holds 60 stocks in biotech, 12% of its weight in S&P 500 companies | IDNA iShares Genomics Immunology and Healthcare ETF Holds 62 stocks in genomics and gene editing, 24% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | Virtus | iShares |
| Theme | Biotech | Genomics and gene editing |
| In the S&P 500 | 12.4% | 23.9% |
| Active share vs the S&P 500 | 99.0% | 99.1% |
| In the Nasdaq-100 | 8.9% | 7.0% |
| Holdings | 60 | 62 |
| Top ten, share of the fund | 25.7% | 46.2% |
| Expense ratio | 0.34% | 0.47% |
| Fee for the differing part | 0.34% | 0.47% |
| Total return, 1 year | +47.5% | +73.4% |
| vs the S&P 500 | +30.9 pts | +56.9 pts |
| vs the Nasdaq-100 | +25.7 pts | +51.7 pts |
| Below its high | −5.5% | −24.7% |
| Net assets | $59m | $271m |
BBP in plain words
By weight, 12% of BBP's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 26% of the fund across 60 positions, as filed for Apr 30, 2026. Over the year to Sep 18, 2026 the fund returned +47.5% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 30.9 pts. It sits 5.5% below its all-time high of Aug 19, 2026.
IDNA in plain words
By weight, 24% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 46% of the fund across 62 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +73.4% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 56.9 pts. It sits 24.7% below its all-time high of Sep 2, 2021.
Questions people ask
- Do BBP and IDNA hold the same stocks?
- By their latest filings, 21% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, BBP or IDNA?
- BBP has 12% of its weight in S&P 500 names and IDNA has 24%, so IDNA differs more from the index.
- Which is cheaper, BBP or IDNA?
- BBP charges 0.34% a year and IDNA charges 0.47%, so BBP is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, BBP against IDNA, data as of Sep 18, 2026. https://etfiq.com/compare/themes/bbp-vs-idna Free to use with attribution; the underlying files are at Open data.